Benzodiazepines for schizophrenia

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2009, Pages

  Volz, Anja ^a   Khorsand, Vesal ^b   Gillies, Donna ^c   Leucht, Stefan ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Gynäkologischgeburtshilfliche Abteilung   (Germany)

^c Western Sydney Area Health Service   (Australia)

Author keywords

Antipsychotic agents adverse effects; *therapeutic use ; Benzodiazepines adverse effects; *therapeutic use ; Randomized controlled trials as topic; Schizophrenia *drug therapy

Indexed keywords

ALPIDEM; ALPRAZOLAM; AMOBARBITAL; BENZODIAZEPINE DERIVATIVE; BROMAZEPAM; CAMAZEPAM; CHLORDIAZEPOXIDE; CHLORPROMAZINE; CLONAZEPAM; CLORAZEPATE DIPOTASSIUM; CLOTIAZEPAM; DIAZEPAM; ESTAZOLAM; FLUNITRAZEPAM; FLUPHENAZINE; FLURAZEPAM; HALOPERIDOL; IMIPRAMINE; LOPRAZOLAM; LORAZEPAM; LORMETAZEPAM; MEDAZEPAM; METACLAZEPAM; MIDAZOLAM; NEUROLEPTIC AGENT; PROCYCLIDINE; PROMETHAZINE; RISPERIDONE; THIORIDAZINE; UNINDEXED DRUG;

AKATHISIA; ALLERGIC REACTION; ANOREXIA; ATAXIA; BIOSIS; BLURRED VISION; CARDIOVASCULAR RESPONSE; CHILL; CINAHL; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COCHRANE LIBRARY; CONFUSION; DEPRESSION; DIARRHEA; DIZZINESS; DROWSINESS; DRUG EFFECT; DRUG TOLERABILITY; DYSARTHRIA; EMBASE; EXCITATION; EXTRAPYRAMIDAL SYMPTOM; FLUSHING; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GRAND MAL SEIZURE; HEADACHE; HEART PALPITATION; HUMAN; INSOMNIA; IRRITABILITY; LACTATION; MEDLINE; MOTOR DYSFUNCTION; NAUSEA; NERVOUSNESS; PARKINSONISM; PSYCHOMOTOR RETARDATION; PSYCINFO; RASH; RESPIRATION DEPRESSION; RESTLESSNESS; REVIEW; SALIVATION; SCHIZOPHRENIA; SEDATION; SEIZURE; SENSORY DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; STOMACH DISEASE; SWEATING; TACHYCARDIA; TARDIVE DYSKINESIA; TREATMENT OUTCOME; TREMOR; VASOMOTOR DISORDER; VOMITING; XEROSTOMIA;

EID: 77950248065     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (115)

1. Azima 1962 {published data only} Azima H, Arthurs D, Silver A. The effects of chlordiazepoxide (librium) in anxiety states: A multi-blind study. Canadian Psychiatric Journal 1962;7(1):44.
2. Barbee 1992 {published data only} Barbee J, Mancuso D, Freed C, Todorov AA. Alprazolam as a neuroleptic adjunct in the emergency treatment of schizophrenia [published erratum appears in American Journal of Psychiatry 1992 ;149(8):1129] [see comments]. American Journal of Psychiatry 1992;149:506-10.
3. Battaglia 1997 {published data only} Battaglia J, Moss S, Rush J, Kang J, Mendoza R, Leedom L, Dubin W, Mc Glynn C, Goodmann L. Haloperidol, lorazepam, or both for psychotic agitation?A multicenter, prospective, double-blind, emergency department study. American Journal of Emergency Medicine 1997;15(4):335-40.
4. Carpenter 1999 {published data only} Carpenter T, Buchanan W, Kirkpatrick B, Breier F. Diazepam Treatment of Early Signs of Exacerbation in Schizophrenia. American Journal of Psychiatry 1999;156(2):299-303.
5. Cheung 1981 {published data only} Cheung H K. Schizophrenics fully remitted on neuroleptics for 3-5 years-To stop or continue drugs?. British Journal of Psychiatry 1981; 138:490-4.
6. Chouinard 1993 {published data only} Chouinard G, Annable L, Turnier L, Holobow N, Szkrumelak N. A double-blind randomized clinical trial of rapid tranquilization with I.M. clonazepam and I.M. haloperidol in agitated psychotic patients with manic symptoms [see comments]. Canadian Journal of Psychiatry 1993;38 Suppl 4:114-21.
7. Dorevitch 1999 {published data only} Dorevitch A, Kalian M, Shlafman M, Lerner V. Treatment of longterm tardive dyskinesia with Vitamin E. Biological Psychiatry 1997; 41:114-6.
8. Dorevith A, Katz N, Zemishlany Z, Aizenberg D, Weizman A. Intramuscular flunitrazepam versus intramuscular haloperidol in the emergency treatment of aggressive psychotic behavior. American Journal of Psychiatry 1999;156:142-4.
9. Foster 1997 {published data only} Foster S, Kessel J, Berman ME, Simpson GM. Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting. International Clinical Psychopharmacology 1997;12:175-9.
10. Garza-Trevino 1989 {published data only} Garza-Trevino ES, Hollister LE, Overall JE, Alexander WF. Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation. American Journal of Psychiatry 1989;146(12):1598-1601.
11. Gundlach 1966 {published data only} Gundlach R, Engelhardt DM, Hankoff L, Paley H, Rudorfer L, Bird E. A Double-blind outpatient study of diazepam (Valium) and placebo. Psychopharmacologia 1966;9:81-92.
12. Guz 1972 {published data only} Guz I. Lorazepam and haloperidol in the treatment of schizophrenic patients [Lorazepam e haloperidol em esquizofrenia]. Jornal Brasileiro de Psiquiatria 1988;37:205-7.
13. Guz I, Moraes R, Sartoretto JN. The therapeutic effects of lorazepam in psychotic patients treated with haloperidol - A double blind study. Current Therapeutic Research 1972;14:767-74.
14. Hankoff 1962 {published data only} Hankoff L, Rudorfer L, Paly HM. A reference study of ataraxics. A two-week double blind outpatient evaluation. The Journal of New Drugs 1962;179:173-8.
15. Hanlon 1969 {published data only} * Hanlon TE, Kay Y, Agallianos D, Berman A, Bethon C, Kolber F, Kurland A. Combined drug treatment of newly hospitalized, acutely ill psychiatric patients. Diseases of the Nervous System 1969; 30(2):169-76.
16. Hanlon 1970 {published data only} Hanlon TE, Kay Y, Kurland A. Comparative effects of fluphenazine, fluphenazine-chlordiazepoxide and fluphenazinei-mipramine. Diseases of the Nervous System 1970;17:1-7.
17. Hanlon TE, Robert JB, Kurland AA. Effects od control techniques on therapeutic outcome in a controlled trial. International Pharmacopsychiatry 1975;10:169-76.
18. Holden 1968 {published data only} Holden JMC, Holden UP.Weight changes with schizophrenic psychosis and psychotropic drug therapy. Psychosomatics 1970;11: 551-61.
19. Holden JMC, Itil TM. Laboratory changes with chlordiazepoxide and thioridazine, alone and combined. Canadian Psychiatric Association Journal 1969;14:299-301.
20. Holden JMC, Itil TM, Keskiner A, Fink M. Thioridazine and chlordiazepoxide, alone and combined, in the treatment of chronic schizophrenia. Comprehensive Psychiatry 1968;9:633-43.
21. Kurland 1966 {published data only} Kurland AA, Bethon GD, Michaux MH, Agallianos DD. Chlorpromazine-chlordiazepoxide and chlorpromazine-imipramine treatment: side effects and clinical laboratory findings. Journal of New Drugs 1966;6:80-95.
22. Michaux MH, Kurland AA, Agallianos DD. Chlorpromazinechlordiazepoxide and chlorpromazine-imipramine treatment of newly hospitalized, acutely ill psychiatric patients. Current Therapeutic Research Clininical and Experimental 1966;8 suppl: 117-52.
23. Kutcher 1989 {published data only} * Kutcher S, Williamson P, MacKenzie S, Marton P, Ehrlich M. Successful clonazepam treatment of neurleptic-induced akathisia in older adolescents and young adults: a double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology 1989;9: 403-6.
24. Lerner 1979 {published data only} Lerner Y, Lwow E, Levitin A, Belmaker RH. Acute high-dose parenteral haloperidol treatment of psychosis. American Journal of Psychiatry 1979;136:1061-4.
25. Lingjaerde 1979 {published data only} Lingjaerde O, Engstrand E, Ellingsen P, Robak OH. Antipsychotic effect of diazepam when given in addition to neuroleptics in chronic psychotic patients - A double-blind clinical trial. Current Therapeutic Research 1979;26(5):505-14.
26. Lingjaerde 1982 {published data only} Lingjaerde O. Effect of the benzodiazepine derivative estazolam in patients with auditory hallucinations. A multicentre double-blind, cross-over study. Acta Psychiatrica Scandinavia 1982;65:339-54.
27. Marneros 1979 {published data only} Marneros A. Anxiolytische Zusatzbehandlung bei der affekbetonten Schizophrenien. Ein Doppelblindversuch. Therapiewoche 29 1979; 44:7533-8.
28. Merlis 1962 {published data only} Merlis S, Turner WJ, Krumholz W. A double-blind comparison of diazepam, chlordiazepoxide and chlorpromazine in psychotic patients. Journal of Neuropsychiatry 1962;3:133-8.
29. Minervini 1990 {published data only} Minervini MG, Priore P, Farolfi A, Cesana B, Morselli PL. Double blind, controlled study of the efficacy and safety of alpidem in the treatment of anxiety in schizophrenic in-patients. Pharmacopsychiatry 1990;23:102-6.
30. Morphy 1986 {published data only} Morphy M. A double-blind comparison of alprazolam and placebo in the treatment of anxious schizophrenic outpatients. Current Therapeutic Research 1986;40:551-60.
31. Nestoros 1982 {published data only} Nestoros JN, Suranyi-Cadotte BE, Spees RC, Schwartz G, Vasavan Nair NP. Diazepam in high doses is effective in schizophrenia. Progress in Neuro- Psychopharmacolgy and Biological Psychiatry 1982; 6(4-6):513-6.
32. Nishikawa 1982 {published data only} Nishikawa T, Tsuda A, Tanaka M, Koga I, Uchida Y. Prophylactic effect of neuroleptics in symptom-free schizophrenics. Psychopharmacology 1982;77:301-4.
33. Pujalte 1994 {published data only} Puljalte D, Battai T, Hue B, Alric R, Pouget R, Blayac JP, Petit P. A double-blind comparison of clonazepam and placebo in the treatment of neuroleptic-induced akathisia. Clinical Neuropharmacology 1994;17(3):236-42.
34. Stevens 1992 {published data only} Stevens A, Stevens I, Mahal A, Gaertner HJ. Haloperidol and lorazepam combined: clinical effects and drug plasma levels in the treatment of acute schizophrenic psychosis. Pharmacopsychiatry 1992;25:273-7.
35. TREC-Rio 2003 {published data only} * TREC Collaborative Group. Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethiazine. British Medical Journal 2003;327:1-6.
36. Wang 2003 {published data only} Wang X, Wang X, Zhou H. An efficacy study of risperidone combined with clonazepam injection in the treatment of paranoid schizophrenia. Journal of Clinical Psychologic Medicine 2003;13(4): 217-8.
37. Wyant 1990 {published data only} Wyant M, Diamond BI, O'Neal E, Sloan A, Borison RL. The use of midazolam in acutely agitated psychiatric patients. Psychopharmacology Bulletin 1990;26:126-9.
38. Adler 1985 {published data only} Adler L, Angrist B, Peselow E, Corwin J, Rotrosen J. Efficacy of propranolol in neuroleptic-induced akathesia. Journal of Clinical Psychopharmacology 1985;5:164-6.
39. Altamura 1987 {published data only} Altamura AC, Mauri MC, Mantero M, Brunetti M. Clonazepam/ haloperidol combination therapy in schizophrenia: A double blind study. Acta Psychiatrica Scandinavica 1987;76:702-6.
40. Ananth 1979 {published data only} * Ananth JV, Sohn JH, Ban TA, Lehmann HE. Doxepin in geriatric patients. Current Therapeutic Research 1979;25:133-8.
41. Bienek 1997 {published data only} Bienek SA, Ownby RL, Dominguez RA. A double-blind study of lorazepam versus the combination of haloperidol and lorazepam in managing agitation. Pharmacotherapy 1998;18(1):57-62.
42. Bobruff 1981 {published data only} Bobruff A, Gardos G, Tarsy D, Rapkin R, Cole J, Moore P. Clonazepam and phenobarbital in tardive dyskinesia. American Journal of Psychiatry 1981;138:189-93.
43. Cohen 1987 {published data only} Cohen S, Khan A. Adjunctive benzodiazepines in acute schizophrenia. Neuropsychobiology 1987;18:9-12.
44. Crosse 1974 {published data only} Crosse B. Clinical trials of sulpiride (1403 R.D. - Dogmatil): Its advantages prescribed alone or in combination [Essais cliniques du sulpiride (1403 R. D. - Dogmatil): Son Intérêt en prescription isolée et en association]. Psychologie Médicale 1974;6(8):1623-30.
45. Csernansky 1988 {published data only} Csernansky JG, Riney SJ, Lombrozo L, Overall JE, Hollister LE. Double-blind comparison fo alprazolam, diazepam, and placebo for the treatment of negative symptoms. Archive General Psychiatry 1988;45:655-9.
46. Csernansky JG, Tacke U, Rusen D, Hollister LE. The effect of benzodiazepines on tardive dyskinesia symptoms. Journal of Clinical Psychopharmacology 1988;8(2):154.
47. Dubin 1988 {published data only} * Dubin W.R. Rapid tranquilization: antipsychotics or benzodiazepines. Journal of Clinical Psychiatry 1988;49:5-11.
48. Greenfeld 1987 {published data only} Greenfeld D, Conrad C, Kincare P, Bowers MB. Treatment of catatonia with low-dose lorazepam. American Journal of Psychiatry 1987;144:1224-5.
49. Haas1982 {published data only} Haas S, Emrich HM, Beckmann H. Analgesic and euphoric effects of high dose diazepam in schizophrenia. Neuropsychobiology 1982; 8:123-8.
50. Hanus 1973 {published data only} Hanus M, Guelfi J. A new tranquilizer: lorazepam (158 cases) [Un nouveau tranquillisant: le Lorazepam (158 observations)]. Semaine des Hopitaux (Therapeutique) 1973;49:349-54.
51. Hartelius 1978 {published data only} Hartelius H, Larsson AK, Lepp M, Malm U, Arvidsson A, Dahlstrom H. A controlled long-term study of flunitrazepam, nitrazepam and placebo, with special regard to withdrawal effects. Acta Psychiatrica Scandinavica 1978;58:1-15.
52. Hekimian 1967 {published data only} Hekimian LJ, Friedhoff AJ. A controlled study of placebo, chlordiazepoxide and chlorpromazine with thirty male Schizophrenic patients. Diseases of Nervous System 1967;28:675-8.
53. Hesso 1975 {published data only} Hesso R, Retterstol N, Torp H. Clinical trial with a new substance (PLP 100-127) in order to asses therapeutic efficacy and dependence creating properties. Behavioral Neuropsychiatry 1975;7: 13-7.
54. Horiguchi 1992 {published data only} Horiguchi J, Nishimatsu O. Usefulness of antiparkinsonian drugs during neuroleptic treatment and the effect of clonazepam on akathisia and parkinsonism occurred after antiparkinsonian drug withdrawal: a double-blind study. Japanese Journal of Psychiatry and Neurology 1992;46:733-9.
55. Itil 1972 {published data only} Itil T, Gannon P, Cora R, Polvan N, Akpinar S, Elveris F, Eskazan E. SCH-12,041, a new anti-anxiety agent (quantitative pharmaco-electroencephalography and clinical trials). Behavioral Neuropsychiatry 1972;4:15-24.
56. Jibiki 1994 {published data only} Jibiki I, Yamaguchi N, Momonoi F. Beneficial effect of high-dose clotiazepam on intractable auditory hallucinations in chronic schizophrenic patients. An open trial. European Journal of Clinical Pharmacology 1994;46:367-9.
57. Jirmeson 1982 {published data only} Jimerson DC, Van Kammen DP, Post RM, Docherty JP, Bunney WE. Diazepam in schizophrenia: a preliminary double-blind trial. American Journal of Psychiatry 1982;139(4):489-91.
58. Jungkunz 1984 {published data only} Jungkunz G, Nedopil N, Ruther E. Acute effects of the synthetic analogue of methionine enkephalin FK 33-824 in schizophrenic patients. A double blind trial. Pharmacopsychiatry 1984;17:76-8.
59. Karson 1982 {published data only} Karson C, Weinberger D, Bigelow L, Wyatt RJ. Clonazepam treatment of chronic schizophrenia: negative results in a doubleblind, placebo-controlled trial. American Journal of Psychiatry 1982; 139:1627-8.
60. Kellner 1975 {published data only} * Kellner R, Wilson RM, Muldawer MD, Pathak D. Anxiety in schizophrenia. The responses to chlordiazepoxide in an intensive design study. Archives of General Psychiatry 1975;32:1246-54.
61. Maar 1983 {published data only} Maar S, Schuback G. Wirkungsvergleich zweier Benzodiazepine bei psychovegetativen Allgemeinstörungen. [Comparison of two benzodiazepines in general psychosomatic disturbances]. Therapiewoche 1983;33:1251-8.
62. Monroe 1967 {published data only} Monroe RR, Dale R. Chlordiazepoxide in the treatment of patients with "activated EEG's". Diseases of Nervous System 1967;28:390-6.
63. Nestros 1983 {published data only} Nestros JN, Nair NPV, Pulman JR, Schwartz G, Bloom D. High doses of diazepam improve neuroleptic-resistant chronic schizophrenic patients. Psychopharmacology 1983;81:42-7.
64. Pato 1989 {published data only} * Pato CN, Wolkowitz OM, Rapaport M, Schulz SC, Pickar D. Benzodiazepine augmentation of neuroleptic treatment in patients with schizophrenia. Psychopharmacology Bulletin 1989;25(2): 263-6.
65. Pecknold 1993 {published data only} * Pecknold JC. Survey of the adjuvant use of benzodiazepines for treating outpatients with schizophrenia. The Journal of Psychiatric Neurosciences 1993;18(2):82-4.
66. Remington 1993 {published data only} * Remington G, Fornazzari L, Setha R. Placebo response in refractory tardive akathisia. Canadian Journal of Psychiatry 1993;38: 248-9.
67. Richards 1998 {published data only} * Richards JR, Derlet RW, Duncan DR. Chemical restraint for the agitated patient in the emergency department: lorazepam versus droperidol. The Journal of Emergency Medicine 1998;16(4):567-73.
68. Ruskin 1978 {published data only} * Ruskin P, Averbush I, Belmaker RH, Dasberg H. Benzodiazepind in chronic schizophrenia. Biological Psychiatry 1979;14(3):557-8.
69. Salam 1988 {published data only} * Salam SA, Kilzieh N. Lorazepam treatment of psyhcogenic catatonia: an update. Journal of Clinical Psychiatry 1988;49(12): 16-21.
70. Saletu 1971 {published data only} * Saletu B, Saletu M, Itil T. Effect of minor and major tranquilizers on somatosensory evoked potentials. Psychopharmacologia 1971;24: 349-58.
71. Soldatos 1986 {published data only} * Soldatos CR, Sakkas PN, Bergiannaki JD, Stefanis CN. Behavioral side effects of triazolam in psychiatric inpatients: report of five cases. Drug Intelligence and Clinical Pharmacy 1986;20: 294-7.
72. Sterlin 1971 {published data only} Sterlin C, Augustin E, Ban TA, Jarrold L. Doxepin as adjuvant medication in the treatment of chronic schizophrenic patients: a comparative study. Current Therapy Research Clinical and Experimental 1971;13:50-2.
73. Stonehill 1966 {published data only} * Stonehill E, Lee H, Ban TA. A comparative study with Benzodiazepines in chronic psychotic patients. Diseases of the Nervous System 1966;27(6):411-3.
74. Subramaney 1997 {published data only} Subramaney U, Brook S, Berk M. A prospective randomised double blind controlled study of the efficacy of Lorazepam versus Clothiapine in the control of acutely behaviourally disturbed patients. 10th ECNP (European College of Neuropsychopharmacology) Congress, Vienna, Austria Sep 13-17, 1997.
75. TREC-Vellore 2004 {published data only} Alexander J, Tharyan P, Adams CE, John T, Mol C, Philip J. Rapid tranquilisation of violent or agitated patients in a psychiatric emergency setting: a pragmatic randomised trial of intramuscular lorazepam versus haloperidol olus promethiazine.. British Journal of Psychiatry 2004;185:63-9.
76. Weber 1983 {published data only} Weber SS, Dufresne RL, Becker RE, Mastrati P. Diazepam in tardive dyskinesia. Drug Intelligence and Clinical Pharmacy 1983; 17:523-7.
77. Wolkowitz 1986 {published data only} Wolkowitz OM, Pickar D, Doran AR, Breier A, Tarell J, Paul SM. Combination alprazolam-neuroleptic treatment of the positive and negative symptoms of schizophrenia. American Journal of Psychiatry 1986;143:85-7.
78. Wolkowitz 1988 {published data only} Wolkowitz OM, Breier A, Doran A, Kelsoe J, Et A. Alprazolam augmentation of the antipsychotic effects of fluphenazine in schizophrenic patients - Preliminary results. Archives of General Psychiatry 1988;45:664-71.
79. Yang 2003 {published data only} Yang X, Wang Z, Ling Z, et al.A randomly controlled comparison of risperidone added with intramuscular clonazepam in the treatment of excitement of schizophrenia. Shanghai Archives of Psychiatry 2003;15(2):98-104.
80. Maculans 1964 {published data only} Maculans GA. Comparison of diazepam, chlorprothixine and chlorpromazine in chronic schizophrenic patients. Diseases of the Nervous System 1964;25:164-8.
81. Salzman 1991 {published data only} Salzman C, Solomon D, Miyawaki E, Glassman R, Rood L, Flowers E, Thayer S. Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior. Journal of Clinical Psychiatry 1991;52:177-80.
82. Ungvari 1999 {published data only} Ungvari GS, Chiu HFK, Chow LY, Lau BST, Tang WK. Lorazepam for chronic catatonia: a randomized, double-blind, placebo-controlled cross-over study. Psychopharmacology 1999;142:393-8.
83. Altman 1996 Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313:1200.
84. Andreasen 1989 Andreasen NC. Scale for the assessment of negative symptoms. British Journal of Psychiatry 1989;155:53-8.
85. Basan 2003 Basan A, Leucht S. Valproate for schizophrenia. Cochrane Database of Systematic Reviews 2003, Issue 3.[Art. No.: CD004028. DOI: 10.1002/14651858.CD004028.pub3]
86. Begg 1996 Beg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schulz KF, Simel D, Stroup DF. Improving the quality of reporting of randomized controlled trials: the CONSORT statement. Journal of American Medicale Assosiation 1996;276:637-9.
87. Bland 1997 Bland JM, Kerry SM. Bland JM, Kerry SM. Statistics notes. Trials randomised in clusters. BMJ 1997, 315:600. Bland JM, Kerry SM. Statistics notes. Trials randomised in clusters.. BMJ 1997;315:600.
88. Cheine 2001 Cheine M, Ahonen J, Wahlbeck K. Beta-blocker supplementation of standard drug treatment for schizophrenia.. Cochrane Database of Systematic Reviews 2001, Issue 3.
89. Christison 1991 Christison GW, Kirch DG, Wyatt RJ. When symptoms persist: choosing among alternative somatic treatments for schizophrenia. Schizophrenia Bulletin 1991;17:217-45.
90. Correll 2003 Correll CU, Rummel C, Kissling W, Kane J, Leucht S. Antipsychotic combinations for schizophrenia. Cochrane Database of Systematic Reviews 2004, Issue 4.
91. Corrigan 1989 Corrigan JD. Development of a scale for assessment of agitation following traumatic brain injury.. Journal of Clinical and Experimental Neuropsychology 1989;11(2):261-77.
92. Deeks 2000 Deeks J. Issues in the selection for meta-analyses of binary data.. Abstracts of 8th International Cochrane Colloquium. Cape Town, South Africa, 2000 Oct 25-28th.
93. Divine 1992 Divine GW, Brown JT, Frazer LM. The unit of analysis error in studies about physicians' patient care behavior.. Journal of General Internal Medicine 1992;7:623-9.
94. Egger 1997 Egger M, Davey mith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315: 629-34.
95. Gillies 2005 Gillies D, Beck A, McCloud A, Rathbone J. Benzodiazepines alone or in combination with antipsychotic drugs for acute psychosis. Cochrane Database of Systematic Reviews 2005, Issue 4.
96. Gulliford 1999 Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994.. American Journal of Epidemiology 1999; 149:876-83.
97. Guy 1976 Guy W. ECDEU Assessment Manual for Psychopharmacology (DOTES: Dosage Record and Treatment Emergent Symptom Scale). Rockville: National Institute of Mental Health, 1976.
98. Guy 1976b Guy. ECDEU assessment manual for psychopharmacology. Maryland: National Institute of Mental Health, 1976.
99. Higgins 2003 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses.. BMJ 2003;327(7414):557- 60.
100. Higgins 2005 Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. The Cochrane Library. Chichester: John Wiley & Sons, Ltd, 2005, issue Issue 3.
101. Honigfeld 1965 Honigfeld G, Klett CJ. The nurses' observation scale for inpatient evaluation. A new scale for measuring improvement in chronic schizophrenia.. Journal of Clinical Psychology 1965;21:65-71.
102. Kay 1987 Kay SR, Fiszbein A. The positive and negative symptome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987;13(2): 261-75.
103. Leucht 2002 Leucht S, McGrath J, White P, Kissling W. Carbamazapine for schizophrenia and schizoaffective psychoses. Cochrane Database of Systematic Reviews 2002, Issue 3.
104. Leucht 2003 Leucht S, McGrath J, Kissling W. Lithium for schizophrenia. Cochrane Database of Systematic Reviews 2003, Issue 3.[Art. No.: CD003834. DOI: 10.1002/14651858.CD003834.pub2]
105. Lorr 1962 Lorr M, McNair DM, Klett CJ, Lasky JJ. Evidence of ten psychotic symptoms. Journal of Consulting Psychology 1962;26:185.
106. Malamud 1947 Malamud W, Sands SL. A revision of the psychiatric rating scale. American Journal of Psychiatry 1947;104:231-37.
107. Marshall 2000 Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia.. British Journal of Psychiatry 2000;176:249-52.
108. Overall 1962 Overall JE, Gorham DR. The brief psychiatric rating scale. Psychological Reports 1962;10:790-812.
109. Schooler 1993 Schooler NR, Keith SJ. Clinical research for the treatment of schizophrenia. Psychopharmacology Bulletin 1993;29:431-46.
110. Schulz 1995 Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273: 408-12.
111. Simpson 1970 Simpson M, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica 1970;212:11-9.
112. Tharyan 2005 Tharyan P. Electroconvulsive therapy for schizophrenia. Cochrane Database of Systematic Reviews 2005, Issue 2.[Art. No.: CD000076. DOI: 10.1002/14651858.CD000076.pub2]
113. Ukoumunne 1999 Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review. Health Technology Assessment 1999;3(5):1-75.
114. Wahlbeck 1999 Wahlbeck K, Cheine MV, Essali A. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database of Systematic Reviews 1999, Issue 4.[Art. No.: CD000059. DOI: 10.1002/14651858.CD000059.pub2]
115. Wahlbeck 2001 Wahlbeck K, Tuunainen A, Ahokas A, Leucht S. Drop-out rates in randomised antipsychotic drug trials.. Psychopharmacology 2001; 155:230-3.